A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis
| Autor: | Yazici, Y. †, ‡, McAlindon, T.E. §, Gibofsky, A. ‖, Lane, N.E. ¶, Lattermann, C. #, Skrepnik, N. ††, Swearingen, C.J. †, Simsek, I. †, Ghandehari, H. †, DiFrancesco, A. †, Gibbs, J. †, Tambiah, J.R.S. †, Hochberg, M.C. ‡‡ |
|---|---|
| Zdroj: | In Osteoarthritis and Cartilage May 2021 29(5):654-666 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect